NICE now backs both Repatha and Praluent

The U.K.'s NICE issued final appraisal determinations (FADs) recommending the use of PCSK9 inhibitors Praluent alirocumab and Repatha evolocumab. The committee backed both drugs for primary non-familial hypercholesterolemia or mixed dyslipidemia in patients with cardiovascular disease (CVD), and primary heterozygous familial hypercholesterolemia (HeFH) in patients with or without CVD.

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) market Praluent, while Amgen Inc. (NASDAQ:AMGN) markets Repatha. The European Commission approved both drugs last year. ...